Phase 3 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children and young people older than 1 month and younger than 18 years of age
- People who have been diagnosed with acute lymphoblastic leukemia (a type of blood cancer), confirmed by a bone marrow test
- People whose leukemia has been identified as the "T-cell" type (called T-ALL) through specialised laboratory testing of the cancer cells
Who may not be able to join:
- People whose leukemia is the "B-cell" type (B-ALL) rather than T-cell type
- People diagnosed with a different type of blood cancer called acute myeloid leukemia (AML)
- People whose leukemia is a mixed or unclear type that cannot be clearly classified, as determined by recognised international medical guidelines
- People whose leukemia developed from a pre-existing blood condition called chronic myeloid leukemia (CML)
- People with Down syndrome, or a major inborn or inherited condition that affects how an organ works
- People whose leukemia developed as a result of a previous cancer treatment (called secondary leukemia)
- People with a known inherited immune system disorder or an inherited condition affecting the body's metabolism
- People with a heart defect present from birth that is causing the heart to not pump properly
- People who have received certain medicines or treatments in the period leading up to the trial — including steroid medicines (glucocorticoids) for 14 days or more, certain targeted medicines called ABL kinase inhibitors for more than 7 days within the past month, or any chemotherapy or radiation therapy within the past 3 months (emergency radiation to relieve airway blockage may be an exception — confirm with trial site)
- People with serious other health conditions or mental health conditions that could affect their safety, ability to follow the study requirements, or the reliability of the results — the trial team assesses these situations individually with the lead researcher
- People with severe malnutrition, an active serious infection, heart failure, or who are unable to tolerate chemotherapy treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Phone: +86 22 23909196
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
End-of-induction(EOI) measurable residual diseases (MRD)-negativity rate in patients with non-ETP T-ALL treated with dasatinib plus 4-drug induction compared to those treated with 4-drug induction in CCCG-ALL-2020; For non-ETP T-ALL patients with positive measurable residual diseases (MRD) on day 46, to compare MRD-negativity rate before consolidation between those receiving single agent homoharringtonine at dose of 1mg/m2 vs. 2mg/m2 for 7 days; End of induction (EOI) measurable residual diseases (MRD)-negativity rate with venetoclax plus 3-drug induction, compared to those treated with 4-drug...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.